Merck (MRK) has had a tumultuous week, marked by both setbacks and breakthroughs. The company scrapped its nemtabrutinib blood cancer program following a risk-benefit review, while simultaneously reporting positive Phase 3 overall survival results for its sacituzumab tirumotecan TroFuse-015 study in gastroesophageal cancer. Despite these mixed developments, Merck's share price has taken a hit, falling 9.5% over the past week and 11.24% over the last 90 days. However, the stock still shows a 25.62% year-to-date gain and a 40.80% total return over 12 months, indicating stronger long-term resilience.
Merck's current trading price of around $133 is significantly below analyst targets and intrinsic value estimates. The consensus fair value stands at $159.76, suggesting a 16% undervaluation. The company plans to introduce over 20 new growth drivers in the coming years, with a potential revenue of more than $70 billion by the mid-2030s. This could help offset future revenue pressure from the loss of exclusivity for KEYTRUDA and support long-term growth.
However, Merck's high P/E ratio of 134.4x raises concerns. This is far above both the industry average of 15.2x and the peer average of 45.6x, indicating that investors are paying a premium for future earnings recovery. If sentiment shifts or forecasts are revised, this valuation risk could become a significant issue. The company's expanding oncology franchise, including sac TMT and the WELIREG plus LENVIMA combination, offers multiple new treatment options but also carries risks related to safety and market uptake.
Analysts highlight mixed signals for Merck, urging investors to review the numbers and weigh key rewards against important warning signs. The company's future depends on its ability to navigate the challenges of KEYTRUDA's exclusivity loss and the success of its newer oncology assets.